Inner City Asthma consortium 3 (ICAC3)

$10,028,067UM1FY2020AINIH

University Of Wisconsin-Madison, Madison WI

Investigators

Linked publications & trials

Paper 39016335 Paper 38869320 Paper 38574825 Paper 38485057 Paper 38416497 Paper 37944567 Paper 37874609 Paper 37660147 Paper 37638498 Paper 37191703 Paper 36754293 Paper 36638920 Paper 36638096 Paper 36608946 Paper 35964610 Paper 35860216 Paper 35660376 Paper 35606880 Paper 35149044 Paper 34862819 Paper 34675193 Paper 34606833 Paper 34561347 Paper 34246436 Paper 34166677 Paper 34019912 Paper 33999100 Paper 33964299 Paper 33713771 Paper 33713764 Paper 33712279 Paper 33606312 Paper 33535024 Paper 33493428 Paper 33434532 Paper 33406429 Paper 33357024 Paper 33159907 Paper 33067429 Paper 32997571 Paper 32828589 Paper 32380068 Paper 32333915 Paper 32246831 Paper 32094926 Paper 32004524 Paper 31926183 Paper 31765853 Paper 31201890 Paper 31046157 Paper 30962590 Paper 30891032 Paper 30529451 Paper 30422897 Paper 30278218 Paper 30213627 Paper 30170124 Paper 30079758 Paper 30059697 Paper 29963059 Paper 29885665 Paper 29755469 Paper 29518416 Paper 29487600 Paper 29449165 Paper 29431692 Paper 29146272 Paper 28987219 Paper 28939248 Paper 28871879 Paper 28870461 Paper 28627361 Paper 28608756 Paper 28238748 Paper 28183432 Paper 28089873 Paper 27993537 Paper 27745942 Paper 27743961 Paper 27720018 Paper 27720017 Paper 27720016 Paper 27654103 Paper 27042305 Paper 26960297 Paper 26947979 Paper 26885707 Paper 26595729 Paper 26589178 Paper 26573086 Paper 26518090 Paper 26414909 Paper 26409873 Paper 26145984 Paper 25979524 Paper 25974301 Paper 25862607 Paper 25129677 Paper 24908147

Abstract

DESCRIPTION (provided by applicant): ICAC's goal is to include further development of cockroach allergen immunotherapy and consideration of new allergen immunotherapies; for example to mouse allergens; the development and execution of clinical and mechanistic studies targeted to inner-city asthma phenotypes, and interventions designed to prevent the incidence of asthma or its progression. In addition, the URECA birth cohort study will be continued to the end of the grant, when the participants will range from 14 to 16 years of age, with the goal to provide information on the immunologic basis of late childhood and adolescence-onset asthma, as well as the remission of asthma during the same years.

View original record on NIH RePORTER →